End-Stage Renal Disease and Renal Replacement Therapy in older Patients

Smyth, Andrew

doi:10.5812/numonthly.1825

Cited by 20 publications

(18 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of technological advancements in dialysis treatment, old age is no longer considered as a contraindication in most industrialized countries [15–18, 21, 22]. Recent studies suggested that dialysis provides a survival benefit compared with conservative management for patients with stages 4-5 chronic kidney disease over the age of 75 years [23–25].…”

Section: Discussionmentioning

confidence: 99%

“…QOL is very important for older patients for whom renal transplantation is an unlikely option. However, very few studies have addressed QOL issues in elderly patients with end-stage renal disease because of the controversial nature of this decision [19, 21, 26]. Lamping et al reported no significant differences in QOL scores between elderly dialysis patients and elderly individuals in the general population in the UK and USA [26].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognosis of Elderly Japanese Patients Aged ≥80 Years Undergoing Hemodialysis

Hatakeyama

Matsubara

Hamano

et al. 2013

The Scientific World Journal

View full text Add to dashboard Cite

Although the number of elderly patients requiring dialysis has increased, data regarding the prognosis of elderly patients undergoing hemodialysis are limited. In the present study, prognosis in Japanese hemodialysis patients aged ≥80 years was evaluated. From January 1988 to July 2013, 1144 consecutive patients with end-stage renal disease required renal replacement therapy at our institution; of these, 141 were aged ≥80 years. These patients' charts were retrospectively reviewed for relevant clinical variables and survival time. The life expectancies table from the National Vital Statistics database was used, and prognostic factors were assessed by multivariate analysis. In total, 107 deaths (76%) were recorded during the study period. The median survival time and estimated life-shortening period in the patients were 2.6 years and −5.3 years, respectively. Eastern Cooperative Oncology Group Performance Status and hemoglobin level were revealed as prognostic factors in the multivariate analysis. Estimates of prognosis and prognostic factors may provide useful information for physicians as well as elderly patients with end-stage kidney disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Prognosis of Elderly Japanese Patients Aged ≥80 Years Undergoing Hemodialysis

Hatakeyama

Matsubara

Hamano

et al. 2013

The Scientific World Journal

View full text Add to dashboard Cite

show abstract

“…We read with interest the article by Smyth A about dialysis indications and the modalities of RRT in elderly patients (1). We would herein underline the particular situation in resource limited areas like sub-Saharan Africa where dialysis access is still very poor and nephrologists have often to make a selection among the growing number of and end-stage renal disease (ESRD) patients who need dialysis (2).…”

mentioning

confidence: 99%

Issues of Renal Replacement Therapy in Elders Living Low-Income African Countries

Seck

2012

Nephro Urol Mon

View full text Add to dashboard Cite

“…It is well known that chronic kidney disease (CKD) is the major cause of ESRD [8] . CKD is caused by divergent disease entities.…”

mentioning

confidence: 99%

Sitagliptin protects rat kidneys from acute ischemia-reperfusion injury via upregulation of GLP-1 and GLP-1 receptors

Chang

Chen

et al. 2014

Acta Pharmacol Sin

View full text Add to dashboard Cite

Aim: Sitagliptin, an oral glucose-lowering agent, has been found to produce cardiovascular protection possibly via anti-inflammatory and anti-atherosclerotic activities of glucagon-like peptide-1 receptor (GLP-1). The aim of this study was to investigate whether sitagliptin protected the kidney function from acute ischemia-reperfusion (IR) injury in rats. Methods: Adult male SD rats were categorized into 4 groups: sham control, IR injury, IR+sitagliptin (300 mg/kg) and IR+sitagliptin (600 mg/kg). Acute renal IR injury of both kidneys was induced by clamping the renal pedicles for 1 h. The drug was orally administered at 1, 24 and 48 h after acute IR. Blood samples and 24-h urine were collected before and at 72 h after acute IR. Then the rats were sacrificed, and the kidneys were harvested for biochemical and immunohistochemical studies. Results: Acute IR procedure markedly increased serum levels of creatinine and BUN and the ratio of urine protein to creatinine. The kidney injury score, inflammatory biomarkers (MMP-9, TNF-α and NF-κB) levels and CD68+ cells in IR kidneys were considerably increased. The expression of oxidized protein, reactive oxygen species (NOX-1, NOX-2) and apoptosis proteins (Bax, caspase-3, PARP) in IR kidneys was also significantly upregulated. All these pathological changes were suppressed by sitagliptin in a dose-dependent manner. Furthermore, the serum GLP-1 level, and the expression of GLP-1 receptor, anti-oxidant biomarkers (HO-1 and NQO-1 cells, as well as SOD-1, NQO-1 and HO-1 proteins), and angiogenesis markers (SDF-1α+ and CXCR4+ cells) in IR kidneys were significantly increased, and further upregulated by sitagliptin. Conclusion: Sitagliptin dose-dependently protects rat kidneys from acute IR injury via upregulation of serum GLP-1 and GLP-1 receptor expression in kidneys.

show abstract

End-Stage Renal Disease and Renal Replacement Therapy in older Patients

Cited by 20 publications

References 48 publications

Prognosis of Elderly Japanese Patients Aged ≥80 Years Undergoing Hemodialysis

Prognosis of Elderly Japanese Patients Aged ≥80 Years Undergoing Hemodialysis

Issues of Renal Replacement Therapy in Elders Living Low-Income African Countries

Sitagliptin protects rat kidneys from acute ischemia-reperfusion injury via upregulation of GLP-1 and GLP-1 receptors

Contact Info

Product

Resources

About